Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population

Figure 1 Study design.

Figure 2 Kaplan-Meier curves for progression free survival (A, left) and overall survival (B, right) according to treatment groups. A: The median progression free survival (mPFS) of the entire cohort was 9.66 mo (95%CI: 7.72–12.5) and there was no statistical difference in mPFS between the oral fluoropyrimidine (FP) group and infusional FP group [9.79 mo (95%CI: 7.49–12.7) vs 9.63 mo (95%CI: 6.34–13.4); log-rank P = 0.72]; B: The median overall survival (mOS) of the entire cohort was 25.8 mo (95%CI: 18.7–35.6) and there was no statistical difference between the oral FP group and infusional FP group [25.8 mo (95%CI: 15.2–35.6) vs 26.3 mo (95%CI: 18.7–41.2); log-rank P = 0.63].

Figure 3 Exploratory predictive factor analyses for progression-free survival (A, above) and overall survival (B, below). A: Age group was shown to modify the effects of chemotherapy backbone on progression-free survival (P = 0.007); B: A similar trend was observed in overall survival (P = 0.050).